Wednesday, June 10, 2026

Drug profile · INN

nusinersen

nusinersen (SPINRAZA) is an FDA-listed pharmaceutical active ingredient. Associated with Biogen.

EMA: approved TGA: approved Musculo-skeletal system (M09) M09
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — nusinersen

Quick answer

nusinersen (SPINRAZA) is an FDA-listed pharmaceutical active ingredient. Associated with Biogen.

Key facts

INN nusinersen
Brand SPINRAZA
Therapeutic class Musculo-skeletal system (M09)
ATC code M09
Originator Biogen

Approval history

Authority Status Date
EMA approved
TGA approved

Recent coverage

Pipeline programs

  1. SPINRAZA 28 mg, SPINRAZA 50 mg Phase 3 · Biogen · Spinal Muscular Atrophy
  2. SPINRAZA 50 mg, SPINRAZA 28 mg Phase 3 · Biogen · Spinal Muscular Atrophy
  3. Spinraza 12 mg solution for injection Phase 1 · Biogen · Spinal Muscular Atrophy
  4. Spinraza 12 mg solution for injection Approved · Biogen · Spinal Muscular Atrophy

Related & competitor drugs

  1. allopurinol Musculo-skeletal system (M04)
  2. colchicine Musculo-skeletal system (M04)
  3. denosumab Musculo-skeletal system (M05)
  4. eteplirsen Musculo-skeletal system (M09)
  5. febuxostat Musculo-skeletal system (M04)
  6. ibandronic acid Musculo-skeletal system (M05)

Frequently asked questions

What is nusinersen?

nusinersen (SPINRAZA) is an FDA-listed pharmaceutical active ingredient. Associated with Biogen.

What is the brand name for nusinersen?

SPINRAZA is a marketed brand name for nusinersen. Check FDA Drugs@FDA for the current US label holder and prescribing information.